Berkshire Hathaway Inc. vs Pfizer Inc.: Strategic Comparison

This in-depth comparison examines Berkshire Hathaway Inc. and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Berkshire Hathaway Inc. on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Berkshire Hathaway Inc. and Pfizer Inc. is widest.

On the headline numbers, Berkshire Hathaway Inc. reports annual revenue of $371.4B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $1.05T and $148.0B. Berkshire Hathaway Inc. is headquartered in United States and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.

Berkshire Hathaway Inc.: Berkshire began as a textile company and became a holding company after Warren Buffett gained control in 1965. The modern company is a collection of operating businesses and investments bound by decentralized management, conservative financing, and a long-term shareholder culture.

Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.

Berkshire Hathaway Inc. and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Berkshire Hathaway Inc. and Pfizer Inc..

Berkshire Hathaway Inc. business model: Berkshire makes money through insurance underwriting and float investment, freight rail, regulated utilities and energy infrastructure, industrial manufacturing, wholesale distribution, retail, services, and a large portfolio of equity and fixed-income investments.

Pfizer Inc. business model: Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Berkshire Hathaway Inc. stack up against those of Pfizer Inc..

Berkshire Hathaway Inc. competitive advantage: Berkshire's advantage is permanent capital, insurance float, a conservative balance sheet, reputation with sellers, and a decentralized culture that attracts owner-minded managers.

Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.

Future prospects matter as much as current results. The growth strategies below explain how Berkshire Hathaway Inc. and Pfizer Inc. each plan to expand from here.

Berkshire Hathaway Inc. growth strategy: Berkshire's growth strategy is not a top-down operating plan; it is disciplined capital allocation. The company reinvests in subsidiaries, buys public equities, acquires private businesses when prices fit, and keeps a fortress balance sheet for downturns.

Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.

A closer look at the financial trajectory of Berkshire Hathaway Inc. and Pfizer Inc. rounds out the comparison.

Berkshire Hathaway Inc.: For FY2025, Berkshire reported $371.444B in revenue and $66.968B in net income attributable to shareholders. Its filing reported about 387,800 employees worldwide at year-end. The updated net income replaces the prior-year comparison figure previously used in this profile.

Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.